Levosimendan - AbbVie/Tenax Therapeutics
Alternative Names: Daxim; ODM 109; OR-1259; Simdax; TNX-101; TNX-102 - Tenax Therapeutics; TNX-103; TNX102Latest Information Update: 02 Sep 2026
At a glance
- Originator Orion
- Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics; Yooyoung Pharmaceutical
- Class Antiarrhythmics; Cardiotonics; Cardiovascular therapies; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
- Mechanism of Action Calcium-binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Yes - Amyotrophic lateral sclerosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute heart failure
- Phase III Amyotrophic lateral sclerosis; Chronic heart failure; Low cardiac output; Pulmonary hypertension
- Discontinued Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks
Most Recent Events
- 29 Aug 2026 Efficacy and adverse events data from phase III clinical trials in Pulmonary hypertension released by Tenax Therapeutics
- 10 Aug 2026 Efficacy and adverse event data from the phase III LEVEL trial in Pulmonary hypertension released by Orion Pharma
- 10 Aug 2026 Updated efficacy, pharmacodynamics and adverse event data from the phase III LEVEL trial in Pulmonary hypertension released by Tenax Therapeutics